NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws ...

The company plans five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. Specialty medicines accounted for more than 80% of GSK's growth in ...

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025.

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

The lawsuit, her office says, seeks to hold GSK accountable for violating laws ... not afford to pay for it out of pocket since the new generic form was not covered.” ...

Pharmaceutical giant GlaxoSmithKline (GSK ... It said it expects further growth to be boosted by its strong pipeline of new drugs, with 71 specialty medicines and vaccines now in clinical development.

still linger, and GSK has to prove its drug development pipeline is packed with new blockbuster treatments.

GSK said it expects core operating profits to rise by between 6% and 8% this year, with turnover set to lift by between 3% and 5%. It added that it expects further growth to be boosted by its strong ...

GSK has increased its long-term sales guidance amid hopes for a boost from new speciality medicines (Andy Buchanan/PA) Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales ...